UV and IR Spectroscopic Studies on Cold Crown Ether Complexes with Metal Ions in 22-Pole Ion Trap

特定領域研究「高次系分子科学」第6回合同班会議, 2011年12月8日-10日, 沖縄残波岬ロイヤルホテル(沖縄県中頭郡読谷村

クラウンエーテルの金属イオン包接錯体の極低温気相分光 : イオン選択性の分子論的理解をめざして

特定領域研究「高次系分子科学」第6回合同班会議, 2011年12月8日-10日, 沖縄残波岬ロイヤルホテル(沖縄県中頭郡読谷村

Ab Initio Structural Energetics of Beta-Si3N4 Surfaces

Motivated by recent electron microscopy studies on the Si3N4/rare-earth oxide interfaces, the atomic and electronic structures of bare beta-Si3N4 surfaces are investigated from first principles. The equilibrium shape of a Si3N4 crystal is found to have a hexagonal cross section and a faceted dome-like base in agreement with experimental observations. The large atomic relaxations on the prismatic planes are driven by the tendency of Si to saturate its dangling bonds, which gives rise to resonant-bond configurations or planar sp^2-type bonding. We predict three bare surfaces with lower energies than the open-ring (10-10) surface observed at the interface, which indicate that non-stoichiometry and the presence of the rare-earth oxide play crucial roles in determining the termination of the Si3N4 matrix grains.Comment: 4 Pages, 4 Figures, 1 tabl

Superconductivity of the Sr2Ca12Cu24O41Sr_2 Ca_{12} Cu_{24} O_{41} spin ladder system: Are the superconducting pairing and the spin-gap formation of the same origin?

Pressure-induced superconductivity in a spin-ladder cuprate Sr$_2$Ca$_{12}$Cu$_{24}$O$_{41}$ has not been studied on a microscopic level so far although the superconductivity was already discovered in 1996. We have improved high-pressure technique with using a large high-quality crystal, and succeeded in studying the superconductivity using $^{63}$Cu nuclear magnetic resonance (NMR). We found that anomalous metallic state reflecting the spin-ladder structure is realized and the superconductivity possesses a s-wavelike character in the meaning that a finite gap exists in the quasi-particle excitation: At pressure of 3.5GPa we observed two excitation modes in the normal state from the relaxation rate $T_1^{-1}$. One gives rise to an activation-type component in $T_1^{-1}$, and the other $T$-linear component linking directly with the superconductivity. This gapless mode likely arises from free motion of holon-spinon bound states appearing by hole doping, and the pairing of them likely causes the superconductivity.Comment: to be published in Phys. Rev. Let

The ground state of Sr3Ru2O7 revisited; Fermi liquid close to a ferromagnetic instability

We show that single-crystalline Sr3Ru2O7 grown by a floating-zone technique is an isotropic paramagnet and a quasi-two dimensional metal as spin-triplet superconducting Sr2RuO4 is. The ground state is Fermi liquid with very low residual resistivity (3 micro ohm cm for in-plane currents) and a nearly ferromagnetic metal with the largest Wilson ratio Rw>10 among paramagnets so far. This contrasts with the ferromagnetic order at Tc=104 K reported on single crystals grown by a flux method [Cao et al., Phys. Rev. B 55, R672 (1997)]. We have also found a dramatic changeover from paramagnetism to ferromagnetism under applied pressure. This suggests the existence of a substantial ferromagnetic instability on the verge of a quantum phase transition in the Fermi liquid state.Comment: 5 pages, 4 figures, to be published in Phys. Rev. B : Rapid co

UV and IR Spectroscopy of Metal Ion-Crown Ether Complexes in the Gas Phase

Seventh International Conference on Advanced Vibrational Spectroscopy (ICAVS-7), 2013年8月25日-30日, 神戸国際会議

極低温イオントラップ中の金属イオン－クラウンエーテル錯体のレーザー分光

第5回分子科学討論会, 2011年9月20日-23日, 札幌コンベンションセンター(札幌

Transcriptional diversity of long-term glioblastoma survivors

BACKGROUND: Glioblastoma (GBM) is a highly aggressive type of glioma with poor prognosis. However, a small number of patients live much longer than the median survival. A better understanding of these long-term survivors (LTSs) may provide important insight into the biology of GBM. METHODS: We identified 7 patients with GBM, treated at Memorial Sloan-Kettering Cancer Center (MSKCC), with survival \u3e48 months. We characterized the transcriptome of each patient and determined rates of MGMT promoter methylation and IDH1 and IDH2 mutational status. We identified LTSs in 2 independent cohorts (The Cancer Genome Atlas [TCGA] and NCI Repository for Molecular Brain Neoplasia Data [REMBRANDT]) and analyzed the transcriptomal characteristics of these LTSs. RESULTS: The median overall survival of our cohort was 62.5 months. LTSs were distributed between the proneural (n = 2), neural (n = 2), classical (n = 2), and mesenchymal (n = 1) subtypes. Similarly, LTS in the TCGA and REMBRANDT cohorts demonstrated diverse transcriptomal subclassification identities. The majority of the MSKCC LTSs (71%) were found to have methylation of the MGMT promoter. None of the patients had an IDH1 or IDH2 mutation, and IDH mutation occurred in a minority of the TCGA LTSs as well. A set of 60 genes was found to be differentially expressed in the MSKCC and TCGA LTSs. CONCLUSIONS: While IDH mutant proneural tumors impart a better prognosis in the short-term, survival beyond 4 years does not require IDH mutation and is not dictated by a single transcriptional subclass. In contrast, MGMT methylation continues to have strong prognostic value for survival beyond 4 years. These findings have substantial impact for understanding GBM biology and progression

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study

Objectives: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease‑modifying antirheumatic drug (DMARD)‑naïve patients with active psoriatic arthritis (PsA). Here, we report longer‑term efficacy and safety to Week 52. Methods: BE OPTIMAL (NCT03895203) comprised a 16‑week, double‑blind, placebo‑controlled period, then 36 weeks treatment‑blind. Patients were randomised 3:2:1 to subcutaneous BKZ 160 mg every 4 weeks (Q4W), PBO with switch to BKZ at Week 16, or reference arm (adalimumab [ADA] 40 mg Q2W). Efficacy outcomes included the American College of Rheumatology (ACR) response criteria 20/50/70, Psoriasis Area and Severity Index (PASI) 75/90/100 in patients with baseline psoriasis affecting ≥3% body surface area, and minimal disease activity (MDA); non‑responder imputation. Results: ACR20/50/70, PASI75/90/100 and MDA responses were sustained with BKZ to Week 52, consistent with results observed at Week 16. Patients who switched to BKZ at Week 16 demonstrated improvements in efficacy with similar results to BKZ‑randomised patients by Week 52. To Week 52, 555/702 (79.1%) patients had ≥1 treatment-emergent adverse event (TEAE) during BKZ treatment; 113/140 (80.7%) on ADA. On BKZ, 46 (6.6%) patients had serious TEAEs and 1 death (0.1%) occurred. 54 (7.7%) Candida infections occurred during BKZ treatment and 1 (0.7%) during ADA; all cases were localised and non‑serious. Conclusions: The efficacy of bimekizumab in bDMARD-naive patients with PsA was sustained from Week 16 to Week 52. BKZ was well tolerated with no new safety signals observed

A global review on short peptides: frontiers and perspectives

Peptides are fragments of proteins that carry out biological functions. They act as signaling entities via all domains of life and interfere with protein-protein interactions, which are indispensable in bio-processes. Short peptides include fundamental molecular information for a prelude to the symphony of life. They have aroused considerable interest due to their unique features and great promise in innovative bio-therapies. This work focusing on the current state-of-the-art short peptide-based therapeutical developments is the first global review written by researchers from all continents, as a celebration of 100 years of peptide therapeutics since the commencement of insulin therapy in the 1920s. Peptide “drugs” initially played only the role of hormone analogs to balance disorders. Nowadays, they achieve numerous biomedical tasks, can cross membranes, or reach intracellular targets. The role of peptides in bio-processes can hardly be mimicked by other chemical substances. The article is divided into independent sections, which are related to either the progress in short peptide-based theranostics or the problems posing challenge to bio-medicine. In particular, the SWOT analysis of short peptides, their relevance in therapies of diverse diseases, improvements in (bio)synthesis platforms, advanced nano-supramolecular technologies, aptamers, altered peptide ligands and in silico methodologies to overcome peptide limitations, modern smart bio-functional materials, vaccines, and drug/gene-targeted delivery systems are discussed